Bradmer Pharmaceuticals (TSE:GLX – Get Free Report) was upgraded by Benchmark to a “strong-buy” rating in a note issued to investors on Monday,Zacks.com reports.
Separately, Cantor Fitzgerald upgraded shares of Bradmer Pharmaceuticals to a “strong-buy” rating in a report on Tuesday, February 25th.
Read Our Latest Analysis on Bradmer Pharmaceuticals
Bradmer Pharmaceuticals Stock Performance
Read More
- Five stocks we like better than Bradmer Pharmaceuticals
- What Investors Need to Know to Beat the Market
- 5 Reasons the S&P 500 Could Rebound Strongly in 2025
- When to Sell a Stock for Profit or Loss
- Best Gold Stocks in 2025… So Far
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- 5 Reasons Why Halliburton is a Good Buy in 2025
Receive News & Ratings for Bradmer Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bradmer Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
